Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;37(10):2129-2132.
doi: 10.1038/s41375-023-02008-6. Epub 2023 Aug 26.

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment

Heinz Gisslinger  1 , Christoph Klade  2 , Pencho Georgiev  3 , Dorota Krochmalczyk  4 , Liana Gercheva-Kyuchukova  5 , Miklos Egyed  6 , Petr Dulicek  7 , Arpad Illes  8 , Halyna Pylypenko  9 , Lylia Sivcheva  10 , Jiří Mayer  11 , Vera Yablokova  12 , Kurt Krejcy  2 , Victoria Empson  2 , Hans C Hasselbalch  13 , Robert Kralovics  14 , Jean-Jacques Kiladjian  15 ; PROUD-PV Study Group
Collaborators, Affiliations

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment

Heinz Gisslinger et al. Leukemia. 2023 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

HG reports grants and personal fees from AOP Health and Novartis, and personal fees from PharmaEssentia and BMS-Pharma. JM reports grants from AOP Health. RK reports personal fees from AOP Health, PharmaEssentia, Qiagen and Novartis and stock ownership in MyeloPro Diagnostics and Research. HH reports Data Monitoring Board honoraria from AOP Health and grants from Novartis. JJK reports grants and personal fees from AOP Health, and personal fees from Novartis, BMS/Celgene, AbbVie and PharmaEssentia. CK, KK, and VE report that they are employees of AOP Health. The remaining authors declare no competing financial interests.

Figures

Fig. 1
Fig. 1. Probability of event-free survival in patients with PV in the ropeginterferon alfa-2b arm and control arm (CONTINUATION-PV full analysis set).
Risk events were defined as thromboembolic events, disease progression or death.
Fig. 2
Fig. 2. Time spent in complete hematologic response by treatment arm.
Time spent in complete hematologic response based on ELN-defined targets for peripheral blood cell counts (hematocrit <45% without phlebotomy for ≥3 months, platelet count <400 × 109/L and leukocyte count <10 × 109/L) for individual patients with PV in the CONTINUATION-PV full analysis set (ropeginterferon alfa-2b arm: panel A; control arm: panel B). Patients are ordered by proportion of time in response (highest to lowest). Blue bars indicate a complete hematologic response at the latest available assessment; yellow bars indicate no response at the latest assessment.
See this image and copyright information in PMC

References

    1. Cuthbert D, Stein BL. Polycythemia vera-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. J Blood Med. 2019;10:359–71. doi: 10.2147/JBM.S189922. - DOI - PMC - PubMed
    1. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874–81. doi: 10.1038/leu.2013.163. - DOI - PMC - PubMed
    1. Abu-Zeinah G, Silver RT, Abu-Zeinah K, Scandura JM. Normal life expectancy for polycythemia vera (PV) patients is possible. Leukemia. 2022;36:569–72. doi: 10.1038/s41375-021-01447-3. - DOI - PubMed
    1. Abu-Zeinah G, Krichevsky S, Cruz T, Hoberman G, Jaber D, Savage N, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021;35:2592–601. doi: 10.1038/s41375-021-01183-8. - DOI - PMC - PubMed
    1. Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196–208. doi: 10.1016/S2352-3026(19)30236-4. - DOI - PubMed

Publication types

MeSH terms

Substances